Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patientsDivij Mathew, Andy J. Minn, Maximillian Diehn et al.|Science|2024Cited by 205
HER2 Expression in Salivary Gland CarcinomasBonnie S. Glisson, Marshall R. Posner, Carmen Summey et al.|Clinical Cancer Research|2004Cited by 202
Complementary and Alternative Medicine Use and Benefit Finding Among Cancer PatientsSheila N. Garland, Jun J. Mao, David C. Valentine et al.|The Journal of Alternative and Complementary Medicine|2013Cited by 82
OA 05.05 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 TrialMyung‐Ju Ahn, D. Kim, D. Ross Camidge et al.|Journal of Thoracic Oncology|2017Cited by 20
P1.01-001 Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK+ NSCLC in the ALTA TrialD. Ross Camidge, D. Kim, Marcello Tiseo et al.|Journal of Thoracic Oncology|2017Cited by 3